ProMIS Q1 net loss $7.3M; completes first cohort enrollment in PRECISE-AD trial

ProMIS Neurosciences Inc.

2025-Q1 EPS reported -$0.21

Net loss $7.3M vs $3.6M YoY; R&D expense $5.5M on PMN310 Phase 1b trial costs.
Cash $8.4M at March 31, 2025, down from $13.3M at Dec 31, 2024.
First cohort fully enrolled and dosed in PRECISE-AD (Phase 1b) for PMN310 in Alzheimer's.
Six-month interim results expected 1H 2026; topline data by end of 2026.
PRECISE-AD designed to detect ARIA with 95% confidence; powered for biomarker changes at 6 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.